HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Milestone Pharmaceuticals (NASDAQ:MIST) and maintained a $25 price target.
August 14, 2023 | 3:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Milestone Pharmaceuticals has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $25.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for Milestone Pharmaceuticals. This could potentially attract investors, driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100